2020 Emerging Cancer Diagnostic Technologies and Supplier Profiles

April 2020 | 110 pages | ID: 2B02E02F74AEN
Venture Planning Group

Abstracts

This report provides detailed assessments of such technologies as monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Also included is a review of competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy.

Contains 110 pages

Contents

1. MONOCLONAL AND POLYCLONAL ANTIBODIES

2. IMMUNOASSAYS

a. Technological Principle
b. Radioimmunoassay (RIA)
c. Enzyme Immunoassays (EIA)
  Overview
  ELISA
  Immunofiltration
  Particle-Membrane Capture Immunoassay
  Enzyme Amplification
d. Fluorescent Immunoassays
e. Luminescence
  Chemiluminescence
  Bioluminescence
f. Latex Agglutination
g. Immunoprecipitation
h. Affinity Chromatographu
e. Liposome Flow-Injection Immunoassay

3. MOLECULAR DIAGNOSTICS

a. Technology Overview
b. Amplification Methods
  PCR
  DAP-PCR
  Immuno-PCR
  QC-PCR
  CAR
  DNA
  HPA
  LCR
  NASBA
  QBR
  SDA
  3 SR, and others

4. CHROMOSOME ANALYSIS

a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence

6. FLOW CYTOMETRY

7. TWO DIMENSIONAL GEL ELECTROPHORESIS (2-DGE)

8. BIOSENSORS

9. COMPETING/COMPLEMENTING TECHNOLOGIES

a. CT
b. MRI
c. NMR
d. PET
e. Photonics Spectroscopy